- Home
- XP vs LEGN Comparison
XP vs LEGN Comparison
Compare XP & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XP | LEGN |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 5.9B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XP | LEGN |
|---|---|---|
| Price | $18.20 | $18.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $22.67 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 6.2M | 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.15 | $46.27 |
| Revenue Next Year | $13.67 | $28.77 |
| P/E Ratio | $11.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.20 | $16.24 |
| 52 Week High | $23.13 | $45.30 |
Technical Indicators
Market Signals| Indicator | XP | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.43 | 49.02 |
| Support Level | $18.05 | $17.46 |
| Resistance Level | $20.37 | $23.68 |
| Average True Range (ATR) | 0.95 | 0.81 |
| MACD | -0.42 | 0.16 |
| Stochastic Oscillator | 0.93 | 47.10 |
Price Performance
Historical ComparisonAbout XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.